Confounding Effects of Metformin on the Human Gut Microbiome in Type 2 Diabetes

Adil Mardinoglu; Jan Boren; Ulf Smith

doi:10.1016/j.cmet.2015.12.012

Confounding Effects of Metformin on the Human Gut Microbiome in Type 2 Diabetes

Cell Metab. 2016 Jan 12;23(1):10-2. doi: 10.1016/j.cmet.2015.12.012.

Authors

Adil Mardinoglu¹, Jan Boren², Ulf Smith³

Affiliations

¹ Science for Life Laboratory, KTH - Royal Institute of Technology, 171 21 Stockholm, Sweden; Department of Biology and Biological Engineering, Chalmers University of Technology, 412 96 Gothenburg, Sweden. Electronic address: adilm@scilifelab.se.
² Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden.
³ Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden; Lundberg Laboratory for Diabetes Research, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.

PMID: 26771114
DOI: 10.1016/j.cmet.2015.12.012

Abstract

Type 2 diabetes (T2D) is associated with dysbiosis of the gut microbiota, though diabetes treatment regimens, including metformin, may confound the results. Forslund et al. (2015) identify distinct disease and drug signatures and highlight the importance of adjusting for treatment when investigating how T2D influences the human gut microbiome.

Publication types

Comment

MeSH terms

Diabetes Mellitus, Type 2 / microbiology*
Female
Gastrointestinal Microbiome / drug effects*
Gastrointestinal Microbiome / physiology*
Humans
Male
Metformin / pharmacology*

Substances

Metformin